Annual Operating Expenses
$116.45 M
+$4.44 M+3.96%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual total operating expenses is currently $116.45 million, with the most recent change of +$4.44 million (+3.96%) on 31 December 2023. During the last 3 years, it has risen by +$50.55 million (+76.70%). EYPT annual operating expenses is now at all-time high.EYPT Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$42.54 M
-$86.00 K-0.20%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly total operating expenses is currently $42.54 million, with the most recent change of -$86.00 thousand (-0.20%) on 30 September 2024. Over the past year, it has increased by +$14.14 million (+49.79%). EYPT quarterly operating expenses is now -3.86% below its all-time high of $44.25 million, reached on 31 March 2024.EYPT Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.0% | +49.8% |
| 3 y3 years | +76.7% | +88.7% |
| 5 y5 years | +323.7% | +161.9% |
EYPT Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +76.7% | -3.9% | +88.7% |
| 5 y | 5 years | at high | +323.7% | -3.9% | +187.9% |
| alltime | all time | at high | >+9999.0% | -3.9% | +2205.5% |
EyePoint Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $42.54 M(-0.2%) |
| June 2024 | - | $42.62 M(-3.7%) |
| Mar 2024 | - | $44.25 M(+50.6%) |
| Dec 2023 | $116.45 M(+4.0%) | $29.38 M(+3.5%) |
| Sept 2023 | - | $28.40 M(-5.6%) |
| June 2023 | - | $30.07 M(+5.2%) |
| Mar 2023 | - | $28.60 M(-5.2%) |
| Dec 2022 | $112.02 M(+33.3%) | $30.16 M(+11.7%) |
| Sept 2022 | - | $27.00 M(-7.0%) |
| June 2022 | - | $29.05 M(+12.6%) |
| Mar 2022 | - | $25.80 M(-2.9%) |
| Dec 2021 | $84.04 M(+27.5%) | $26.56 M(+17.8%) |
| Sept 2021 | - | $22.55 M(+24.8%) |
| June 2021 | - | $18.06 M(+7.1%) |
| Mar 2021 | - | $16.87 M(-3.1%) |
| Dec 2020 | $65.90 M(+0.6%) | $17.41 M(+10.4%) |
| Sept 2020 | - | $15.77 M(+6.8%) |
| June 2020 | - | $14.77 M(-17.7%) |
| Mar 2020 | - | $17.95 M(+10.2%) |
| Dec 2019 | $65.54 M(+138.4%) | $16.29 M(+0.3%) |
| Sept 2019 | - | $16.24 M(-2.6%) |
| June 2019 | - | $16.67 M(+2.1%) |
| Mar 2019 | - | $16.33 M(+16.3%) |
| Dec 2018 | $27.49 M(-6.0%) | - |
| Sept 2018 | - | $14.04 M(+33.8%) |
| June 2018 | $29.23 M(+11.9%) | $10.50 M(+87.2%) |
| Mar 2018 | - | $5.61 M(-16.8%) |
| Dec 2017 | - | $6.74 M(+5.5%) |
| Sept 2017 | - | $6.39 M(-6.5%) |
| June 2017 | $26.11 M(+11.6%) | $6.84 M(+18.9%) |
| Mar 2017 | - | $5.75 M(-5.2%) |
| Dec 2016 | - | $6.07 M(-18.7%) |
| Sept 2016 | - | $7.46 M(+10.4%) |
| June 2016 | $23.39 M(+16.1%) | $6.76 M(+24.7%) |
| Mar 2016 | - | $5.42 M(-6.0%) |
| Dec 2015 | - | $5.76 M(+5.8%) |
| Sept 2015 | - | $5.45 M(-2.8%) |
| June 2015 | $20.14 M | $5.61 M(+4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $5.38 M(+16.0%) |
| Dec 2014 | - | $4.64 M(+2.6%) |
| Sept 2014 | - | $4.52 M(+4.9%) |
| June 2014 | $17.04 M(+20.2%) | $4.31 M(+2.2%) |
| Mar 2014 | - | $4.21 M(+0.2%) |
| Dec 2013 | - | $4.21 M(-2.5%) |
| Sept 2013 | - | $4.32 M(-3.5%) |
| June 2013 | $14.17 M(+1.9%) | $4.47 M(+34.5%) |
| Mar 2013 | - | $3.33 M(+2.8%) |
| Dec 2012 | - | $3.23 M(+2.9%) |
| Sept 2012 | - | $3.14 M(+4.5%) |
| June 2012 | $13.91 M(-7.1%) | $3.01 M(-7.8%) |
| Mar 2012 | - | $3.27 M(-5.2%) |
| Dec 2011 | - | $3.44 M(-17.8%) |
| Sept 2011 | - | $4.19 M(+4.2%) |
| June 2011 | $14.97 M(+7.2%) | $4.02 M(+15.0%) |
| Mar 2011 | - | $3.50 M(-1.0%) |
| Dec 2010 | - | $3.54 M(-9.6%) |
| Sept 2010 | - | $3.91 M(+10.2%) |
| June 2010 | $13.96 M(-16.9%) | $3.55 M(+5.0%) |
| Mar 2010 | - | $3.38 M(-4.7%) |
| Dec 2009 | - | $3.55 M(+1.6%) |
| Sept 2009 | - | $3.49 M(+6.5%) |
| June 2009 | $16.80 M(-40.8%) | $3.28 M(-16.9%) |
| Mar 2009 | - | $3.94 M(-10.2%) |
| Dec 2008 | - | $4.39 M(+48.5%) |
| Sept 2008 | - | $2.96 M(-61.8%) |
| June 2008 | $28.38 M(-24.9%) | $7.75 M(+8.3%) |
| Mar 2008 | - | $7.15 M(-12.4%) |
| Dec 2007 | - | $8.16 M(+342.5%) |
| Sept 2007 | - | $1.84 M(-79.5%) |
| June 2007 | $37.78 M(+29.6%) | - |
| Dec 2006 | - | $9.01 M |
| June 2006 | $29.14 M(+92.1%) | - |
| June 2005 | $15.17 M(+133.4%) | - |
| June 2004 | $6.50 M(+77.1%) | - |
| June 2003 | $3.67 M(+104.5%) | - |
| June 2002 | $1.80 M(+264.6%) | - |
| June 2001 | $492.40 K | - |
FAQ
- What is EyePoint Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual operating expenses year-on-year change?
- What is EyePoint Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly operating expenses year-on-year change?
What is EyePoint Pharmaceuticals annual total operating expenses?
The current annual operating expenses of EYPT is $116.45 M
What is the all time high annual operating expenses for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual total operating expenses is $116.45 M
What is EyePoint Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, EYPT annual total operating expenses has changed by +$4.44 M (+3.96%)
What is EyePoint Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of EYPT is $42.54 M
What is the all time high quarterly operating expenses for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly total operating expenses is $44.25 M
What is EyePoint Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, EYPT quarterly total operating expenses has changed by +$14.14 M (+49.79%)